-
Something wrong with this record ?
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry
A. Brioli, E. Lomaia, C. Fabisch, T. Sacha, H. Klamova, E. Morozova, A. Golos, P. Ernst, U. Olsson-Stromberg, D. Zackova, FE. Nicolini, H. Bao, F. Castagnetti, E. Patkowska, J. Mayer, K. Hirschbühl, H. Podgornik, E. Paczkowska, A. Parry, T....
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
ProQuest Central
from 2000-01-01 to 1 year ago
Open Access Digital Library
from 1997-01-01
Nursing & Allied Health Database (ProQuest)
from 2000-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 2000-01-01 to 1 year ago
Public Health Database (ProQuest)
from 2000-01-01 to 1 year ago
- MeSH
- Blast Crisis * pathology MeSH
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive * drug therapy pathology therapy mortality MeSH
- Adult MeSH
- Transplantation, Homologous MeSH
- Protein Kinase Inhibitors * therapeutic use MeSH
- Tyrosine Kinase Inhibitors MeSH
- Middle Aged MeSH
- Humans MeSH
- Disease Management MeSH
- Survival Rate MeSH
- Adolescent MeSH
- Young Adult MeSH
- Follow-Up Studies MeSH
- Prognosis MeSH
- Registries * MeSH
- Aged MeSH
- Hematopoietic Stem Cell Transplantation methods MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Europe MeSH
Blast phase (BP) of chronic myeloid leukemia (CML) still represents an unmet clinical need with a dismal prognosis. Due to the rarity of the condition and the heterogeneity of the biology and clinical presentation, prospective trials and concise treatment recommendations are lacking. Here we present the analysis of the European LeukemiaNet Blast Phase Registry, an international collection of the clinical presentation, treatment and outcome of blast phases which had been diagnosed in CML patients after 2015. Data reveal the expected heterogeneity of the entity, lacking a clear treatment standard. Outcomes remain dismal, with a median overall survival of 23.8 months (median follow up 27.8 months). Allogeneic stem cell transplantation (alloSCT) increases the rate of deep molecular responses. De novo BP and BP evolving from a previous CML do show slightly different features, suggesting a different biology between the two entities. Data show that outside clinical trials and in a real-world setting treatment of blast phase is individualized according to disease- and patient-related characteristics, with the aim of blast clearance prior to allogeneic stem cell transplantation. AlloSCT should be offered to all patients eligible for this procedure.
3 Med Klinik Med Fakultät Mannheim Universität Heidelberg Mannheim Germany
Abteilung für Innere Medizin 4 Klinikum Wels Grieskirchen Wels Austria
Centre Hospitalier Annecy Genevois Annecy France
Centre Léon Bérard Hématology Départment and CRCL INSERM U590 Lyon France
Department of General Pathology Pomeranian Medical University in Szczecin Szczecin Poland
Department of Haematology University Medical Centre Ljubljana Ljubljana Slovenia
Department of Hematology Jagiellonian University Medical College Cracow Poland
Department of Hematology Jagiellonian University Medical College Krakow Poland
Department of Hematology University Hospital Uppsala Uppsala Sweden
Faculty of Pharmacy University of Ljubljana Ljubljana Slovenia
Hematology and Oncology Faculty of Medicine University of Augsburg Augsburg Germany
Hematology Center after Prof R Yeolyan Yerevan Armenia
Hematology Department Institute of Hematology and Transfusion Medicine Warsaw Poland
Hematooncology Department Copernicus Memorial Hospital Lodz Poland
Institute of Hematology and Blood Transfusion Prague Czech Republic
IRCCS Azienda Ospedaliero Universitaria di Bologna Istituto di Ematologia Seràgnoli Bologna Italy
Klinikum Passau Klinik für Onkologie Hämatologie und Palliativmedizin Passau Germany
Oncology Centre of the Podkarpackie Province Department of Hematooncology Brzozow Poland
Onkologische Schwerpunktpraxis Anhut Kronach Germany
Servicio de Hematología Hospital General Universitario de Toledo Toledo Spain
Uniklinik Erlangen Medizinische Klinik 5 Erlangen Germany
Zentrum für Innere Medizin Hämatologie Onkologie Stauferklinikum Schwäbisch Gmünd Mutlangen Germany
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24014099
- 003
- CZ-PrNML
- 005
- 20240905133509.0
- 007
- ta
- 008
- 240725s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41375-024-02204-y $2 doi
- 035 __
- $a (PubMed)38548962
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Brioli, Annamaria $u Klinik und Poliklinik für Innere Medizin C, Hämatologie und Onkologie, Universitätsmedizin Greifswald, Greifswald, Germany. brioli.annamaria@mh-hannover.de $u Klinik für Innere Medizin II, Universitätsklinikum Jena, Comprehensive Cancer Center Central Germany, Campus Jena, Jena, Germany. brioli.annamaria@mh-hannover.de $u Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation, Medizinische Hochschule Hannover, Hannover, Germany. brioli.annamaria@mh-hannover.de $1 https://orcid.org/0000000240727592
- 245 10
- $a Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry / $c A. Brioli, E. Lomaia, C. Fabisch, T. Sacha, H. Klamova, E. Morozova, A. Golos, P. Ernst, U. Olsson-Stromberg, D. Zackova, FE. Nicolini, H. Bao, F. Castagnetti, E. Patkowska, J. Mayer, K. Hirschbühl, H. Podgornik, E. Paczkowska, A. Parry, T. Ernst, A. Voskanyan, E. Szczepanek, S. Saussele, GN. Franke, A. Kiani, E. Faber, S. Krause, LF. Casado, K. Lewandowski, M. Eder, P. Anhut, J. Gil, T. Südhoff, H. Hebart, S. Heibl, M. Pfirrmann, A. Hochhaus, M. Lauseker
- 520 9_
- $a Blast phase (BP) of chronic myeloid leukemia (CML) still represents an unmet clinical need with a dismal prognosis. Due to the rarity of the condition and the heterogeneity of the biology and clinical presentation, prospective trials and concise treatment recommendations are lacking. Here we present the analysis of the European LeukemiaNet Blast Phase Registry, an international collection of the clinical presentation, treatment and outcome of blast phases which had been diagnosed in CML patients after 2015. Data reveal the expected heterogeneity of the entity, lacking a clear treatment standard. Outcomes remain dismal, with a median overall survival of 23.8 months (median follow up 27.8 months). Allogeneic stem cell transplantation (alloSCT) increases the rate of deep molecular responses. De novo BP and BP evolving from a previous CML do show slightly different features, suggesting a different biology between the two entities. Data show that outside clinical trials and in a real-world setting treatment of blast phase is individualized according to disease- and patient-related characteristics, with the aim of blast clearance prior to allogeneic stem cell transplantation. AlloSCT should be offered to all patients eligible for this procedure.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a blastická krize $x patologie $7 D001752
- 650 12
- $a chronická myeloidní leukemie $x farmakoterapie $x patologie $x terapie $x mortalita $7 D015464
- 650 12
- $a registrace $7 D012042
- 650 12
- $a inhibitory proteinkinas $x terapeutické užití $7 D047428
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a mladý dospělý $7 D055815
- 650 _2
- $a homologní transplantace $7 D014184
- 650 _2
- $a transplantace hematopoetických kmenových buněk $x metody $7 D018380
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a míra přežití $7 D015996
- 650 _2
- $a management nemoci $7 D019468
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a inhibitory tyrosinkinasy $7 D000092004
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Lomaia, Elza $u Research Department of Immuno-Oncology, Almazov National Medical Research Centre, Saint Petersburg, Russian Federation $1 https://orcid.org/0000000332907961
- 700 1_
- $a Fabisch, Christian $u Klinik für Innere Medizin II, Universitätsklinikum Jena, Comprehensive Cancer Center Central Germany, Campus Jena, Jena, Germany
- 700 1_
- $a Sacha, Tomasz $u Department of Hematology, Jagiellonian University Medical College, Krakow, Poland $1 https://orcid.org/0000000272076595
- 700 1_
- $a Klamova, Hana $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 700 1_
- $a Morozova, Elena $u Raisa Gorbacheva memorial Research Institute for Pediatric Oncology, Hematology, Transplantation, First State Pavlov Medical University of Saint Petersburg, Saint Petersburg, Russian Federation
- 700 1_
- $a Golos, Aleksandra $u Hematooncology Department, Copernicus Memorial Hospital, Lodz, Poland
- 700 1_
- $a Ernst, Philipp $u Klinik für Innere Medizin II, Universitätsklinikum Jena, Comprehensive Cancer Center Central Germany, Campus Jena, Jena, Germany $1 https://orcid.org/0000000151659874
- 700 1_
- $a Olsson-Stromberg, Ulla $u Department of Hematology, University Hospital Uppsala, Uppsala, Sweden
- 700 1_
- $a Zackova, Daniela $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
- 700 1_
- $a Nicolini, Franck E $u Centre Léon Bérard, Hématology Départment and CRCL INSERM U590, Lyon, France
- 700 1_
- $a Bao, Han $u Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie (IBE), Medizinische Fakultät, Ludwig-Maximilians-Universität München, Munich, Germany
- 700 1_
- $a Castagnetti, Fausto $u IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy $u Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy $1 https://orcid.org/0000000206022628
- 700 1_
- $a Patkowska, Elzbieta $u Hematology Department, Institute of Hematology and Transfusion Medicine, Warsaw, Poland $1 https://orcid.org/0000000186914310
- 700 1_
- $a Mayer, Jiri $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
- 700 1_
- $a Hirschbühl, Klaus $u Hematology and Oncology, Faculty of Medicine, University of Augsburg, Augsburg, Germany $1 https://orcid.org/0000000248477460
- 700 1_
- $a Podgornik, Helena $u Department of Haematology, University Medical Centre Ljubljana, Ljubljana, Slovenia $u Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia $1 https://orcid.org/0000000337522067
- 700 1_
- $a Paczkowska, Edyta $u Department of General Pathology, Pomeranian Medical University in Szczecin, Szczecin, Poland $1 https://orcid.org/0000000170529741
- 700 1_
- $a Parry, Anne $u Centre Hospitalier Annecy Genevois, Annecy, France
- 700 1_
- $a Ernst, Thomas $u Klinik für Innere Medizin II, Universitätsklinikum Jena, Comprehensive Cancer Center Central Germany, Campus Jena, Jena, Germany $1 https://orcid.org/000000032147489X
- 700 1_
- $a Voskanyan, Astghik $u Hematology Center after Prof. R. Yeolyan, Yerevan, Armenia
- 700 1_
- $a Szczepanek, Elzbieta $u Department of Hematology, Jagiellonian University Medical College, Cracow, Poland
- 700 1_
- $a Saussele, Susanne $u III. Med. Klinik, Med. Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany $1 https://orcid.org/0000000303575785
- 700 1_
- $a Franke, Georg-Nikolaus $u University of Leipzig Medical Center, Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Diseases, Comprehensive Cancer Center Central Germany, Campus Leipzig, Leipzig, Germany $1 https://orcid.org/000000018239002X
- 700 1_
- $a Kiani, Alexander $u Medizinische Klinik IV, Klinikum Bayreuth GmbH, Bayreuth, and Comprehensive Cancer Center Erlangen-EMN, Bayreuth, Germany $1 https://orcid.org/0000000224944087
- 700 1_
- $a Faber, Edgar $u Department of Hemato-Oncology, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Krause, Stefan $u Uniklinik Erlangen, Medizinische Klinik 5, Erlangen, Germany $1 https://orcid.org/0000000252594651
- 700 1_
- $a Casado, Luis Felipe $u Servicio de Hematología, Hospital General Universitario de Toledo, Toledo, Spain
- 700 1_
- $a Lewandowski, Krzysztof $u Department of Hematology & Bone Marrow Transplantation, Poznań University of Medical Sciences, Poznań, Poland
- 700 1_
- $a Eder, Matthias $u Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation, Medizinische Hochschule Hannover, Hannover, Germany
- 700 1_
- $a Anhut, Peter $u Onkologische Schwerpunktpraxis Anhut, Kronach, Germany
- 700 1_
- $a Gil, Justyna $u Oncology Centre of the Podkarpackie Province, Department of Hematooncology, Brzozow, Poland
- 700 1_
- $a Südhoff, Thomas $u Klinikum Passau, Klinik für Onkologie, Hämatologie und Palliativmedizin, Passau, Germany
- 700 1_
- $a Hebart, Holger $u Zentrum für Innere Medizin, Hämatologie/Onkologie, Stauferklinikum Schwäbisch Gmünd, Mutlangen, Germany $1 https://orcid.org/0000000345369955
- 700 1_
- $a Heibl, Sonja $u Abteilung für Innere Medizin IV, Klinikum Wels-Grieskirchen, Wels, Austria
- 700 1_
- $a Pfirrmann, Markus $u Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie (IBE), Medizinische Fakultät, Ludwig-Maximilians-Universität München, Munich, Germany
- 700 1_
- $a Hochhaus, Andreas $u Klinik für Innere Medizin II, Universitätsklinikum Jena, Comprehensive Cancer Center Central Germany, Campus Jena, Jena, Germany
- 700 1_
- $a Lauseker, Michael $u Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie (IBE), Medizinische Fakultät, Ludwig-Maximilians-Universität München, Munich, Germany. lauseker@ibe.med.uni-muenchen.de $1 https://orcid.org/0000000266627127
- 773 0_
- $w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 38, č. 5 (2024), s. 1072-1080
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38548962 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240725 $b ABA008
- 991 __
- $a 20240905133503 $b ABA008
- 999 __
- $a ok $b bmc $g 2143710 $s 1225965
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 38 $c 5 $d 1072-1080 $e 20240328 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
- LZP __
- $a Pubmed-20240725
